

a
sequence, GRGDSP (SEQ ID NO:46) or a monomer such as GVGVAP (SEQ ID NO:47) or VGVAPG (SEQ ID NO:52), which is a chemoattractant for fibroblasts and monocytes. On the larger side (90-100 amino acids), the second peptide can be a cell attachment sequence from the Type-III domains of fibronectin, vitronectin, tenascin, titin or other related cell attachment protein, which sequence provides more specific cell attachment than the somewhat non-specific GRGDSP cell attachment sequence.--

IN THE CLAIMS

Q2
Claim 13 (Amended).

The method of Claim 4 wherein said second peptide unit comprises a cell attachment sequence from the Type-III domains of fibronectin, vitronectin, tenascin, titin and other related cell attachment proteins.

W3
Claim 34 (Amended).

The method of Claim 23 wherein said tissue site is periurethral, subdermal, tendon or cartilage.

CANCEL
CANCEL Claims 35-75.

REMARKS

The Amendment

Claims 13 and 34 are amended to correct grammatical errors. The amended claims are presented above in a "clean" form, as required under 37 CFR1.121(c)(1)(i). In addition, a marked up version of the claims, showing additions (underlined) and deletions (bracketed) is presented in the attached page pursuant to 37 CFR1.121(c).

The Specification has been amended to recite continuing data information. Support therefor can be found, for example, on the Transmittal filed with the application.

The Specification is amended to correct a typographical error. The amended paragraph is presented above in a "clean" form, as required under 37 CFR1.121(b)(1)(ii). In addition, a marked up version of the replacement paragraph, showing additions (underlined) and deletions (bracketed) is presented in the attached page pursuant to 37 CFR1.121(b).

No new matter has been added.